Table 6. Cost results breakdown of the model in a hypothetical cohort of 1,000 patients–per member per month (incremental costs [ABA-1L vs. TNFi-1L]).
| Base case | CPI | Point rate | ≥65 years | <65 years | Duration ≥5 years | Duration <5 years | J-HAQ <1.5 | J-HAQ ≥1.5 | |
|---|---|---|---|---|---|---|---|---|---|
| bDMARD | -1,456 | -1,456 | -1,456 | -1,456 | -1,456 | -1,456 | -1,456 | -1,456 | -1,456 |
| Concomitant medication | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 |
| Monitoring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AEs occurring ≥5% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SAEs | -257 | -263 | -261 | 129 | -1,042 | -347 | 28 | -477 | -78 |
| Hospitalisations due to infections | 153 | 157 | 154 | 153 | 153 | 153 | 153 | 153 | 153 |
| Total | -1,571 | -1,573 | -1,574 | -1,185 | -2,357 | -1,661 | -1,287 | -1,792 | -1,392 |
1L, first line; ABA, abatacept; AE, adverse event; bDMARD, biological disease-modifying antirheumatic drug; CPI, consumer price index; J-HAQ, Japanese version of Health Assessment Questionnaire; Point rate, official revision rates per expense item; SAE, serious AE; TNFi, tumour necrosis factor inhibitor.